GGrantIndex
← Search

Genome Editing Shared Resource

$171,743P30FY2022CANIH

Vanderbilt University Medical Center, Nashville TN

Investigators

Linked publications, trials & patents

Trial NCT07016399Trial NCT06593106Trial NCT05501665Trial NCT05361720Trial NCT04765072Trial NCT02702310Trial NCT02685631Trial NCT02677883Trial NCT02676752Trial NCT02672475Trial NCT02658487Trial NCT02600533Trial NCT02489422Trial NCT02480114Trial NCT02457910Trial NCT02448225Trial NCT02440737Trial NCT02374931Trial NCT02359851Trial NCT02324881Trial NCT02296112Trial NCT02269111Trial NCT02240381Trial NCT02236546Trial NCT02170272Trial NCT02151539Trial NCT02148406Trial NCT01996527Trial NCT01928160Trial NCT01901367Trial NCT01660971Trial NCT01230515Trial NCT01198535Trial NCT01141218Trial NCT01098669Trial NCT01098643Trial NCT01096407Trial NCT01096394Trial NCT01096381Trial NCT01077440Trial NCT01031446Trial NCT01013506Trial NCT01009931Trial NCT01007422Trial NCT00993694Trial NCT00993135Trial NCT00987766Trial NCT00984542Trial NCT00984490Trial NCT00983268Trial NCT00957736Trial NCT00949052Trial NCT00930930Trial NCT00900406Trial NCT00900003Trial NCT00899769Trial NCT00899626Trial NCT00899457Trial NCT00899301Trial NCT00899028Trial NCT00898742Trial NCT00898638Trial NCT00898430Trial NCT00898313Trial NCT00897988Trial NCT00897832Trial NCT00897793Trial NCT00897650Trial NCT00897468Trial NCT00897403Trial NCT00897117Trial NCT00896948Trial NCT00896675Trial NCT00892801Trial NCT00875238Trial NCT00840814Trial NCT00837876Trial NCT00835679Trial NCT00801346Trial NCT00765245Trial NCT00755040Trial NCT00675636Trial NCT00670644Trial NCT00670605Trial NCT00670046Trial NCT00666211Trial NCT00656604Trial NCT00653250Trial NCT00651976Trial NCT00651716Trial NCT00647218Trial NCT00626873Trial NCT00625417Trial NCT00625066Trial NCT00616590Trial NCT00601991Trial NCT00573404Trial NCT00550537Trial NCT00544648Trial NCT00533884

Abstract

CORE 008 – GENOME EDITING SHARED RESOURCE PROJECT SUMMARY/ABSTRACT The mission of the Genome Editing Shared Resource (GESR), previously the Transgenic Mouse/Embryonic Stem Cell Shared Resource, is to enable the Vanderbilt-Ingram Cancer Center (VICC) research community, inclusive of our VICC members and partners at Meharry Medical College, Tennessee State University, and other NCI Cancer Centers to efficiently generate, store and share genetically-altered mouse models. GESR, which has been in existence for over 25 years, has undergone major changes over the past five years. Five prior service lines oriented around gene targeting in mouse embryonic stem cells (mESCs) became unnecessary after the discovery of CRISPR/Cas9. Thus, in late 2015, GESR shifted its focus towards improving the efficiency and outcomes of CRISPR/Cas9-mediated gene editing in one and two cell mouse embryos. Since then, over 800 mutant mice from 97 CRISPR/Cas9 experiments have been generated, with a 100% technical success rate for the past twenty-six projects. GESR now provides a full-service approach where the resource performs project design, pre-injection reagent validation, post-injection analysis of the resulting pups, and breeding of the first generation to provide the investigator with a correctly edited heterozygous mouse. Investigators no longer need extensive molecular biology skills, or even much knowledge about CRISPR/Cas9 gene editing strategies. To support the sharing of these new CRISPR-generated lines, GESR has become more proactive in encouraging the use of core cryopreservation services. In house cryopreservation of mouse lines improves colony management and enables specific pathogen free stocks to be sent as cryopreserved germplasm to other institutions. The resource continues to reconstitute cryopreserved mouse lines that are requested by VICC investigators from other investigators, or that exist within external repositories, by performing both in vitro fertilization and embryo transfer. Finally, the resource has established, and are striving to expand, a Vanderbilt Cryopreserved Mouse Repository (VCMR). The VCMR facilitates compliance with NIH Mouse Sharing Policies and enables storage and distribution of mice from Vanderbilt without the continued involvement of investigators. All microinjection and embryo transfer services are performed in a specific pathogen free barrier facility. Together, the combination of services provided by the GESR enables VICC members and other Vanderbilt investigators to efficiently generate and maintain novel genome-edited mouse models to study multiple aspects of cell and tumor biology using sophisticated mouse models.

View original record on NIH RePORTER →